Pro-inflamatory components of nutrition as one of reasons of a growing incidence of the chronic non-communicable diseases
Authors:
P. Šíma 1; B. Turek 2; V. Bencko 3
Authors‘ workplace:
Mikrobiologický ústav v. v. i., AV ČR, Praha Ředitel: RNDr. Martin Bilej, DrSc.
1; Společnost pro výživu Předseda: MUDr. Petr Tláskal, CSc.
2; Ústav hygieny a epidemiologie 1. LF UK a VFN, Praha Přednosta: doc. MUDr. Milan Tuček, CSc.
3
Published in:
Prakt. Lék. 2014; 94(1): 32-37
Category:
Of different specialties
Overview
A growing number of in vitro/in vivo experimental and clinical studies documents that the products of non-enzymatic reactions formed during technological and culinary processing of food may play a major role in the emergence and global spreading of chronic non-infectious diseases. Evidence mainly points towards a pathogenic role for advanced glycation end products (AGE), advanced lipoxidation end products (ALE), and advanced oxidation protein products (AOPP), which represent the most important dietary compounds that accumulate within the internal milieu of an organism during the whole life span. Currently, they are often regarded as one of a row of causations having strong negative influence on the health and causative agents of chronic diseases burden in all countries, which adopt the westernized lifestyle.
Keywords:
westernized lifestyle – chronic disease – processed foods – AGE – ALE – AOPP
Sources
1. Agalou S, Ahmed N, Dawnay A, Thornally P.J. Removal of advanced glycation products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochem. Soc Trans 2003; 31: 1394–1396.
2. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertension 2003; 21: 3–12.
3. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. J Parenter Enteral Nutr 2006; 30: 45–51.
4. Bengmark S. Advanced glycation and lipoxidation end products-amplifiers of inflammation: the role of food. J Parenter Enteral Nutr 2007; 31: 430–440.
5. Cerami A, Vlassara H, Brownlee M. Glucose and aging. Sci Am 1987; 256: 90–96.
6. Delatour T, Hegele J, Parisod V, et al. Analysis of advanced glycation endproducts in dairy products by isotope dilution liquid chromatography-electrospray tandem mass spectrometry. The particular case of carboxymethyllysine. J Chromatogr A 2009; 1216: 2371–2381.
7. Dragland S, Senoo H, Wake K, et al. Several culinary and medicinal herbs are important sources of dietary antioxidants. Nutr 2003; 133: 1286–1290.
8. Gorelik S, Ligumsky M, Kohen R, Kanner J. The stomach as a "bioreactor": when red meat meets red wine. J Agric Food Chem 2008; 56: 5002–5007.
9. Hu S, He W, Liu Z, Xu H, Ma G. The acumulation of the glycoxidation product N(ε)-carboxymethyllysine in cardiac tissues with age, diabetes mellitus and coronary heart disease. Tohoku J Exp Med 2013; 230: 25–32.
10. Januszewski AS, Thomas MC, Chung SJ, et al. Plasma low-molecular weight fluorescence in type 1 diabetes mellitus. Ann NY Acad Sci 2005; 1043: 655–661.
11. Kalousová M, Škrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51: 597–604.
12. Klune JR, Dhupar R, Cardinal J, et al. HMGB1: endogenous danger signalling. Mol Med 2008; 14: 476–484.
13. Lee S, Lee K.-W. Protective effect of epigallocatechin gallate aginst advance glycation end products- induced injury in neuronal cells. Biol Pharmaceut Bull 2007; 30: 1369–1373.
14. Lin L. RAGE on the Toll road? Cell Mol Immunol 2006; 3: 351–358.
15. Maeshima T, Honda K, Chikazawa M, et al. Quantitative analysis of acrolein-specific adducts generated during lipid peroxidation-modification of proteins in vitro: identification of N(τ)-(3-propanal)histidine as the major adduct. Chem Res Toxicol 2012; 25: 1384–1392.
16. Maillard LC. Action des acids amine sur des sucres: formation des melanoides per voie methodique. CR Acad Sci 1912; 154: 66–68.
17. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006; 26: 430–437.
18. Nandhini ATA, Thirunavakkarasu V, Anuradha CV. Stimulation of glucose utilisation and inhibition of protein glycation and AGE products by taurine. Acta Physiol Scand 2004; 181: 297–303.
19. Osawa T, Kato Y. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann NY Acad Sci 2005; 1043: 440–451.
20. Pulverer G, Beuth J, Roszkowski W, et al. Bacteria of human physiological microflora liberate immunomodulating peptides. Zentralbl Bakteriol 1990; 272: 467–476.
21. Qin Q, Niu J, Wang Z, et al. Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathway. Cardiovasc Diabetol 2013; 12: 37–46.
22. Roszkowski K, Ko KL, Beuth J, et al. Intestinal microflora of BALB/c mice and function of local immune cells. Zentralbl. Bakteriol. Microbiol. Hyg A 1988; 270: 270–279.
23. Schmidt AM, Yan SD, Yan SF, Stem DM. The multiligand receptor RAGE is a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949–955.
24. Sharp PS, Rainbow S, Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med 2003; 20: 575–579.
25. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004; 4: 469–478.
26. Šíma P. Chronický únavový syndrom. Interní Med 2010; 12: 419–423.
27. Šíma P, Turek B, Bencko V. Nutriční imunologie: modulace imunity složkami nutrice. Prakt. Lék. 2013; 93: 158–162.
28. Vlassara H, Cai J, Crandall J, et al. Inflammatory mediators are induced by dietry glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99: 15596–15601.
29. World Health Organization. Process for global strategy on diet, physical activity and health. Geneva: WHO 2003.
30. Yamagishi S, Fujimori H, Yonekura H, et al. Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998; 41: 1435–1441.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2014 Issue 1
Most read in this issue
- Paediatric trigger finger
- Problems in quality of life assessment in seniors
- Concept of the branch of General Practice
- Immunoglobulin substitution therapy in patients with primary immunodeficiency